Efficacy, Safety, and Drug–Drug Interactions for Insomnia Therapy in COVID-19 Patients

Saputra, Billy Dwi; Levita, Jutti; Mustarichie, Resmi

doi:10.2147/jmdh.s337053

Cited by 6 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypnotics, sedatives, and anxiolytics can be used to treat insomnia, but the use of these anti-insomnia drugs is associated with various safety concerns. [41] At present, exercise therapy for COVID-19 has been proposed; resistance training or aerobic exercise is beneficial for improving physiological function and reducing depression and anxiety in COVID-19-infected patients. [42] The present study has several limitations.…”

Section: Discussionmentioning

confidence: 99%

Insomnia among coronavirus disease 2019 survivors: A single-center cross-sectional study

Lu,

Zhu,

et al. 2024

Medicine

View full text Add to dashboard Cite

Since the coronavirus disease 2019 (COVID-19) epidemic, insomnia has become one of the longer COVID-19 symptoms. This study aimed to investigate insomnia among COVID-19 survivors and explore the occurrence and influencing factors of insomnia. A cross-sectional study was performed from December 2022 to February 2023 through an online questionnaire star survey with 8 questions. The insomnia severity index scale (ISI) was used to assess the severity of insomnia. Univariate analysis was used to analyze the factors related to COVID-19 infection. A total of 564 participants (183 males and 381 females) were surveyed in the present study. The prevalence of insomnia was 63.12%. Among these insomnia patients, there were 202 (35.82%) with sub-threshold symptoms, 116 (20.57%) with moderate symptoms, and 38 (6.74%) with severe symptoms. Univariate analysis indicated that there were statistically significant differences in the prevalence of insomnia among COVID-19 survivors of different ages, occupations, and educational levels (P < .05). Of the 356 insomnia patients, 185 (51.97%) did not take any measures against insomnia, while those who took drugs only, physical exercise only, drugs and physical exercise, and other measures were 90 (25.28%), 42 (11.80%), 17 (4.78%), and 22 (6.18%), respectively. Additionally, of the 107 insomnia patients with drug therapy, 17 (15.89%) took estazolam, 16 (14.95%) took alprazolam, 39 (36.45%) took zopiclone, and 35 (32.71%) took other drugs to improve insomnia symptoms. The prevalence of insomnia symptoms remains high among COVID-19 survivors in China. Education level and occupation may be the influencing factors. Unfortunately, most patients with insomnia do not take corresponding treatment measures.

show abstract

Section: Discussionmentioning

confidence: 99%

Insomnia among coronavirus disease 2019 survivors: A single-center cross-sectional study

Lu,

Zhu,

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Efficacy, Safety and Drug-Drug Interactions for Insomnia Therapy in COVID-19 Patients 19 and Potential anti-alopecia constituents from Theobroma cacao: An in silico Study. 20 When viewed from the Gibss bond free energy parameters (ΔG) and the inhibition constant (Ki), the best values were for Methylhidroxy calcone and Cinnamic compounds.…”

Section: Binding Compounds -Cinnamon Compounds With Orexin Receptorsmentioning

confidence: 99%

Molecule Attachment and Prediction of ADMET Compounds in Cinnamomum burmannii on Orexin Receptor as Anti-insomnia

Mustarichie¹,

Saptarini²,

Megantara³

2022

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Insomnia is a sleep disorder characterized by a person's dissatisfaction with the quantity or quality of sleep. Suvorexant is a sedative and hypnotic drug that has been shown to be useful for the treatment of insomnia and can act more centrally and selectively on the orexin system. However, suvorexant has quite a lot of side effects. According to research, cinnamon has pharmacological benefits, one of which is anti-insomnia. The aimed this study to determine the interaction between the compounds contained in the cinnamon plant and the Orexin receptor with the molecular anchoring method and to determine the prediction of the ADMET properties of cinnamon compounds which have the potential as anti-insomniac. Material and Methods: The research method was in-silico study consisted of validation, bonding of cinnamon compounds and prediction of ADMET properties. Results: The results showed that cinnamon compounds, namely Cinnamic acid and Methylhidroxy calcone, had the best interactions with lower Gibbs bond energy values (ΔG) and inhibition constants (Ki). From the results of the prediction of ADMET properties, the Methylhydroxy calcone compound obtained positive results on the hepatotoxicity parameter and the Cinnamic acid compound obtained negative results, which means that the compound does not have toxic properties. Conclusion: The Cinnamic acid could be used as a new promising anti-insomnia agent.

show abstract

Dynamics of drug contamination of the river-water in the rural, semirural and urban areas of the Mrežnica River in Croatia during COVID-19 pandemic (2020–2021)

Stipaničev¹,

Dragun

Repec³

et al. 2023

Environ Sci Pollut Res

View full text Add to dashboard Cite

Efficacy, Safety, and Drug–Drug Interactions for Insomnia Therapy in COVID-19 Patients

Cited by 6 publications

References 42 publications

Insomnia among coronavirus disease 2019 survivors: A single-center cross-sectional study

Insomnia among coronavirus disease 2019 survivors: A single-center cross-sectional study

Molecule Attachment and Prediction of ADMET Compounds in Cinnamomum burmannii on Orexin Receptor as Anti-insomnia

Dynamics of drug contamination of the river-water in the rural, semirural and urban areas of the Mrežnica River in Croatia during COVID-19 pandemic (2020–2021)

Contact Info

Product

Resources

About